Plasma Chromogranin A Response to Octreotide Test: Prognostic Value for Clinical Outcome in Endocrine Digestive Tumors

Yao, 2008, One hundred years after carcinoid: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States., J Clin Oncol, 26, 3063, 10.1200/JCO.2007.15.4377

Ramage, 2005, Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumors., Gut, 54, iv1, 10.1136/gut.2004.053314

Modlin, 2008, Gastroenteropancreatic neuroendocrine tumors., Lancet Oncol, 9, 61, 10.1016/S1470-2045(07)70410-2

Delaunoit, 2008, Medical management of pancreatic neuroendocrine tumors., Am J Gastroenterol, 103, 475, 10.1111/j.1572-0241.2007.01643.x

Modlin, 2008, Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors., J Natl Cancer Inst, 100, 1282, 10.1093/jnci/djn275

Warner, 2005, Enteroendocrine tumors other than carcinoid: a review of clinically significant advances., Gastroenterology, 128, 1668, 10.1053/j.gastro.2005.03.078

Massironi, 2008, Neuroendocrine tumors of the gastro-entero-pancreatic system., World J Gastroenterol, 14, 5377, 10.3748/wjg.14.5377

Steinmuller, 2008, Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary., Neuroendocrinology, 87, 47, 10.1159/000111037

Zatelli, 2007, Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study., Endocr Relat Cancer, 14, 473, 10.1677/ERC-07-0001

Campana, 2007, Chromogranin A: is it a useful marker of neuroendocrine tumors?, J Clin Oncol, 25, 1967, 10.1200/JCO.2006.10.1535

Arnold, 2008, Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors., Clin Gastroenterol Hepatol, 6, 820, 10.1016/j.cgh.2008.02.052

Ardill, 2008, Circulating markers for endocrine tumours of the gastroenteropancreatic tract., Ann Clin Biochem, 45, 539, 10.1258/acb.2008.008039

Ardill, 2003, The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut., Endocr Relat Cancer, 10, 459, 10.1677/erc.0.0100459

Nehar, 2004, Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours., Clin Endocrinol, 60, 644, 10.1111/j.1365-2265.2004.02030.x

Oberg, 2004, Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system., Ann Oncol, 15, 966, 10.1093/annonc/mdh216

Oberg, 2009, Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors., Expert Rev Anticancer Ther, 9, 557, 10.1586/era.09.26

Butturini, 2006, Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma., Endocr Relat Cancer, 13, 1213, 10.1677/erc.1.01200

Panzuto, 2006, Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma., Ann Oncol, 17, 461, 10.1093/annonc/mdj113

Shojamanesh, 2002, Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma., Cancer, 94, 331, 10.1002/cncr.10195

Rinke, 2009, Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group., J Clin Oncol, 27, 4656, 10.1200/JCO.2009.22.8510

Cimitan, 2003, Somatostatin receptor scintigraphy versus chromogranin A assay in the managment of patients with neuroendocrine tumors of different types: clinical role., Annals Oncol, 14, 1135, 10.1093/annonc/mdg279

Namwongprom, 2008, Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors., Ann Nucl Med, 22, 237, 10.1007/s12149-007-0123-y

Oberg, 2008, Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up., Ann Oncol, 19, ii104, 10.1093/annonc/mdn117

Sundin, 2007, Nuclear imaging of neuroendocrine tumours., Best Pract Res Clin Endocrinol Metab, 21, 69, 10.1016/j.beem.2006.12.003

Shi, 1998, The octreotide suppression test and 111In-DTPA-D-Phe1-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment., Clin Endocrinol, 48, 303, 10.1046/j.1365-2265.1998.00373.x

Kos-Kudla, 2007, Octreotide suppression test in diagnosing and predicting the outcome of therapy in patients with neuroendocrine tumors. Preliminary report., Endokrynol Pol, 58, 123

Moattari, 1989, Effects of sandostatin on plasma chromogranin-A levels in neuroendocrine tumors., J Clin Endocrinol Metab, 69, 902, 10.1210/jcem-69-4-902

Bajetta, 2006, Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study., Cancer, 107, 2474, 10.1002/cncr.22272

Rindi, 2006, European Neuroendocrine Tumor Society (ENETS). TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system., Virchows Arch, 449, 395, 10.1007/s00428-006-0250-1

Rindi, 2007, TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system., Virchows Arch, 451, 757, 10.1007/s00428-007-0452-1

Peracchi, 2003, Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1., Eur J Endocrinol, 148, 39, 10.1530/eje.0.1480039

Peracchi, 2005, Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids., Eur J Endocrinol, 152, 443, 10.1530/eje.1.01862

Kolby, 2003, Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours., Br J Surg, 90, 687, 10.1002/bjs.4149

Fazio, 2007, Interferon-alpha and somatostatin analogs in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?, Ann Oncol, 18, 13, 10.1093/annonc/mdl144

Volante, 2007, Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy., Mod Pathol, 20, 1172, 10.1038/modpathol.3800954

Faiss, 2003, Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumorsthe International Lanreotide and Interferon Alfa Study Group., J Clin Oncol, 21, 2689, 10.1200/JCO.2003.12.142

Fykse, 2004, Treatment of ECL cell carcinoids with octreotide LAR., Scand J Gastroenterol, 39, 621, 10.1080/00365520410005225

Manfredi, 2007, Pagenault M, de Lajarte-Thirouard AS et al. Type 1 and 2 gastric carcinoid tumors: long term follow-up of the efficacy of treatment with a slow release somatostatin analogue., Eur J Gastroenterol Hepatol, 19, 1021, 10.1097/MEG.0b013e328220eae0

Campana, 2008, Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs., Endocr Relat Cancer, 15, 337, 10.1677/ERC-07-0251

Grozinsky-Glasberg, 2008, Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours., Eur J Endocrinol, 159, 475, 10.1530/EJE-08-0420